首页 | 本学科首页   官方微博 | 高级检索  
   检索      


T-cell Receptor-optimized Peptide Skewing of the T-cell Repertoire Can Enhance Antigen Targeting
Authors:Julia Ekeruche-Makinde  Mathew Clement  David K Cole  Emily S J Edwards  Kristin Ladell  John J Miles  Katherine K Matthews  Anna Fuller  Katy A Lloyd  Florian Madura  Garry M Dolton  Johanne Pentier  Anna Lissina  Emma Gostick  Tiffany K Baxter  Brian M Baker  Pierre J Rizkallah  David A Price  Linda Wooldridge  Andrew K Sewell
Institution:From the Institute of Infection and Immunity, Cardiff University School of Medicine, Henry Wellcome Building, Heath Park, Cardiff CF14 4XN, Wales, United Kingdom, ;the §Australian Centre for Vaccine Development, Human Immunity Laboratory, Queensland Institute of Medical Research, Brisbane 4029, Australia, and ;the Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556
Abstract:Altered peptide antigens that enhance T-cell immunogenicity have been used to improve peptide-based vaccination for a range of diseases. Although this strategy can prime T-cell responses of greater magnitude, the efficacy of constituent T-cell clonotypes within the primed population can be poor. To overcome this limitation, we isolated a CD8+ T-cell clone (MEL5) with an enhanced ability to recognize the HLA A*0201-Melan A27–35 (HLA A*0201-AAGIGILTV) antigen expressed on the surface of malignant melanoma cells. We used combinatorial peptide library screening to design an optimal peptide sequence that enhanced functional activation of the MEL5 clone, but not other CD8+ T-cell clones that recognized HLA A*0201-AAGIGILTV poorly. Structural analysis revealed the potential for new contacts between the MEL5 T-cell receptor and the optimized peptide. Furthermore, the optimized peptide was able to prime CD8+ T-cell populations in peripheral blood mononuclear cell isolates from multiple HLA A*0201+ individuals that were capable of efficient HLA A*0201+ melanoma cell destruction. This proof-of-concept study demonstrates that it is possible to design altered peptide antigens for the selection of superior T-cell clonotypes with enhanced antigen recognition properties.
Keywords:Immunology  Immunotherapy  Major Histocompatibility Complex (MHC)  T-cell Receptor  Vaccine Development
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号